Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results

被引：1

作者：

Sitbon, Olivier ^{[1
]}

Channick, Richard ^{[2
]}

Chin, Kelly ^{[3
]}

Frey, Aline ^{[4
]}

Galie, Nazzareno ^{[5
]}

Ghofrani, Hossein-Ardeschir ^{[6
]}

Hoeper, Marius M. ^{[7
,8
]}

Lang, Irene ^{[9
]}

Le Brun, Franck-Olivier ^{[4
]}

McLaughlin, Vallerie ^{[10
]}

Preiss, Ralph ^{[4
]}

Rubin, Lewis J. ^{[11
]}

Simonneau, Gerald ^{[1
]}

Tapson, Victor ^{[12
]}

Gaine, Sean ^{[13
]}

机构：

[1] Univ Paris Sud, Hop Univ Bicetre, Le Kremlin Bicetre, France

[2] Massachusetts Gen Hosp, Pulm & Crit Care, Boston, MA 02114 USA

[3] Univ Texas Southwestern Med Ctr Dallas, Pulm Hypertens Program, Dallas, TX 75390 USA

[4] Actel Pharmaceut Ltd, Clin Res, Allschwil, Switzerland

[5] Univ Bologna, Ist Malattie Apparato Cardiovasc, Bologna, Italy

[6] UGMLC, Giessen, Germany

[7] Hannover Med Sch, Dept Resp Med, Hannover, Germany

[8] German Ctr Lung Res, Hannover, Germany

[9] Med Univ Vienna, AKH, Dept Internal Med 2, Div Cardiol, Vienna, Austria

[10] Univ Michigan Hlth Syst, Div Cardiovasc Med, Ann Arbor, MI USA

[11] Univ Calif San Diego, Div Pulm & Crit Care Med, San Diego, CA 92103 USA

[12] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA

[13] Mater Misericordiae Univ Hosp, Natl Pulm Hypertens Unit, Dublin, Ireland

来源：

EUROPEAN RESPIRATORY JOURNAL | 2015年 / 46卷

关键词：

Pulmonary hypertension;

D O I：

10.1183/13993003.congress-2015.OA4995

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

OA4995

引用

页数：3

共 50 条

[41] Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study
Hoeper, Marius M.
Corris, Paul A.
Ghofrani, Hossein-Ardeschir
Klinger, James R.
Langleben, David
Naeije, Robert
Simonneau, Gerald
Jansa, Pavel
Rosenkranz, Stephan
Grunig, Ekkehard
Scelsi, Laura
Meier, Christian
Busse, Dennis
Benza, Raymond L.
EUROPEAN RESPIRATORY JOURNAL, 2017, 50
[42] Effect of Riociguat on Pulmonary Arterial Compliance in Patients With Pulmonary Arterial Hypertension (PAH) in the Respite Study
Thenappan, Thenappan
Hoeper, Marius
Corris, Paul
Ghofrani, Hossein-Ardeschir
Klinger, James
Langleben, David
Naeije, Robert
Simonneau, Gerald
Jansa, Pavel
Rosenkranz, Stephan
Grunig, Ekkehard
Scelsi, Laura
Meier, Christian
Busse, Dennis
Benza, Raymond
CHEST, 2017, 152 (04) : 1005A - 1006A
[43] REAL-WORLD USE OF SELEXIPAG AND OTHER PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPIES: AN OBSERVATIONAL COHORT STUDY IN PATIENTS WITH PAH (EXPOSURE)
Muller, A.
Soderberg, S.
Escribano, P.
Biedermann, P.
Sun, H.
Lange, T. J.
Gaine, S.
VALUE IN HEALTH, 2019, 22 : S602 - S603
[44] TARGETING THE PROSTACYCLIN PATHWAY IN THE TREATMENT OF CONNECTIVE TISSUE DISEASE ASSOCIATED PULMONARY ARTERIAL HYPERTENSION (PAH): INSIGHTS FROM THE RANDOMISED CONTROLLED GRIPHON TRIAL WITH SELEXIPAG
Coghlan, G.
Gaine, S.
Channick, R.
Di Scala, L.
Galie, N.
Ghofrani, H. A.
Hoeper, M. M.
Lang, I.
McLaughlin, V.
Preiss, R.
Rubin, L. J.
Simonneau, G.
Sitbon, O.
Tapson, V. F.
Chin, K.
THORAX, 2016, 71 : A65 - A65
[45] Targeting The Prostacyclin Pathway In The Treatment Of Connective Tissue Disease Associated Pulmonary Arterial Hypertension (pah): Insights From The Randomized Controlled Griphon Trial With Selexipag
Gaine, S. P.
Channick, R. N.
Di Scala, L.
Galie, N.
Ghofrani, H. -A.
Hoeper, M. M.
Lang, I.
McLaughlin, V.
Preiss, R.
Rubin, L. J.
Simonneau, G.
Sitbon, O.
Tapson, V.
Chin, K. M.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
[46] Long-term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension
Tamura, Yuichi
Furukawa, Asuka
Tamura, Yudai
Yamada, Kenta
Taniguchi, Hirohisa
Fukuda, Keiichi
Kawamura, Akio
Satoh, Toru
PULMONARY CIRCULATION, 2022, 12 (01)
[47] Cardiopulmonary Resuscitation Outcomes in Patients with Pulmonary Arterial Hypertension (PAH)
Mathers, H.
Pebley, N. B.
Odish, M. F.
Papamatheakis, D. G.
Poch, D. S.
Kim, N. H.
Fernandes, T. M.
Wardi, G.
Sell, R. E.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
[48] Long-term effects of bosentan in pulmonary arterial hypertension to connective tissue disease (PAH-CTD): The TRUST study results.
Denton, Christopher P.
Gabrielli, Armando
Peter, Hans-Hartmut
Morganti, Adele
Pope, Janet
Guillevin, Loic
ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S740 - S740
[49] Long-term effects of bosentan in pulmonary arterial hypertension related to connective tissue disease (PAH-CTD): The trust study results
Denton, C. P.
Gabrielli, A.
Peter, H.
Morganti, A.
Pope, J. E.
Guillevin, L.
JOURNAL OF RHEUMATOLOGY, 2007, 34 (07) : 1622 - 1622
[50] Effect of Macitentan on Long-term Outcomes in Patients With Pulmonary Arterial Hypertension (PAH): Subanalysis of SERAPHIN Comparing Incident and Prevalent Patient Populations Not Treated With Background PAH-Specific Therapy
Simonneau, Gerald
Channick, Richard
Delcroix, Marion
Galie, Nazzareno
Ghofrani, Hossein
Jansa, Pavel
Le Brun, Franck-Olivier
Mehta, Sanjay
Perchenet, Loic
Pulido, Tomas
Sastry, B.
Sitbon, Olivier
Souza, Rogerio
Torbicki, Adam
Rubin, Lewis
CHEST, 2013, 144 (04)

← 1 2 3 4 5 →